They achieve this by inhibiting CD8+ T cell activation, upregulating PD-L1 expression in tumor cells, secreting TGF-β1, and interfering with Arachidonate 15-Lipoxygenase (ALOX15) expression, thereby promoting tumor progression (121–124). This evidence concerns the gene CD8A and neoplasm.